Patent Expirations Mean Changes in Drug Development Landscape

While an estimated $125 billion of patent-protected drug revenue is at risk in the next few years, replacements in the drug development pipeline pale in comparison to existing blockbusters. As a result, the current drug development landscape will require major changes in how clinical research is conducted, Kenneth Getz, senior research fellow at the Tufts Center for the Study of Drug Development, says.
Washington Drug Letter